157 related articles for article (PubMed ID: 35351058)
1. Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients.
Spohn SKB; Adebahr S; Huber M; Jenkner C; Wiehle R; Nagavci B; Schmucker C; Carl EG; Chen RC; Weber WA; Mix M; Rühle A; Sprave T; Nicolay NH; Gratzke C; Benndorf M; Wiegel T; Weis J; Baltas D; Grosu AL; Zamboglou C
BMC Cancer; 2022 Mar; 22(1):337. PubMed ID: 35351058
[TBL] [Abstract][Full Text] [Related]
2. PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01).
Zamboglou C; Spohn SKB; Ruf J; Benndorf M; Gainey M; Kamps M; Jilg C; Gratzke C; Adebahr S; Schmidtmayer-Zamboglou B; Mix M; Bamberg F; Zschaeck S; Ghadjar P; Baltas D; Grosu AL
Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1025-1035. PubMed ID: 35469897
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial.
Zamboglou C; Spohn SKB; Adebahr S; Huber M; Kirste S; Sprave T; Gratzke C; Chen RC; Carl EG; Weber WA; Mix M; Benndorf M; Wiegel T; Baltas D; Jenkner C; Grosu AL
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830950
[TBL] [Abstract][Full Text] [Related]
5. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
6. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
Dewes S; Schiller K; Sauter K; Eiber M; Maurer T; Schwaiger M; Gschwend JE; Combs SE; Habl G
Radiat Oncol; 2016 May; 11():73. PubMed ID: 27229485
[TBL] [Abstract][Full Text] [Related]
7. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
9. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
10. PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial.
Ménard C; Young S; Zukotynski K; Hamilton RJ; Bénard F; Yip S; McCabe C; Saad F; Brundage M; Nitulescu R; Bauman G
BMC Cancer; 2022 Mar; 22(1):251. PubMed ID: 35260100
[TBL] [Abstract][Full Text] [Related]
11. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.
Jiang P; Krockenberger K; Vonthein R; Tereszczuk J; Schreiber A; Liebau S; Huttenlocher S; Imhoff D; Balermpas P; Keller C; Dellas K; Baumann R; Rödel C; Hildebrandt G; Jünemann KP; Merseburger AS; Katz A; Ziegler A; Blanck O; Dunst J
Radiat Oncol; 2017 Aug; 12(1):138. PubMed ID: 28821268
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.
Valle L; Shabsovich D; de Meerleer G; Maurer T; Murphy DG; Nickols NG; Vapiwala N; Calais J; Kishan AU
Eur Urol Oncol; 2021 Jun; 4(3):339-355. PubMed ID: 33637464
[TBL] [Abstract][Full Text] [Related]
14. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
15. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
Dearnaley DP; Hall E; Lawrence D; Huddart RA; Eeles R; Nutting CM; Gadd J; Warrington A; Bidmead M; Horwich A
Br J Cancer; 2005 Feb; 92(3):488-98. PubMed ID: 15685244
[TBL] [Abstract][Full Text] [Related]
16. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
18. TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol.
Martin J; Keall P; Siva S; Greer P; Christie D; Moore K; Dowling J; Pryor D; Chong P; McLeod N; Raman A; Lynam J; Smart J; Oldmeadow C; Tang CI; Murphy DG; Millar J; Tai KH; Holloway L; Reeves P; Hayden A; Lim T; Holt T; Sidhom M
BMJ Open; 2019 Aug; 9(8):e030731. PubMed ID: 31434782
[TBL] [Abstract][Full Text] [Related]
19. Three wound-dressing strategies to reduce surgical site infection after abdominal surgery: the Bluebelle feasibility study and pilot RCT.
Reeves BC; Rooshenas L; Macefield RC; Woodward M; Welton NJ; Waterhouse BR; Torrance AD; Strong S; Siassakos D; Seligman W; Rogers CA; Rickard L; Pullyblank A; Pope C; Pinkney TD; Pathak S; Owais A; O'Callaghan J; O'Brien S; Nepogodiev D; Nadi K; Murkin CE; Munder T; Milne T; Messenger D; McMullan CM; Mathers JM; Mason M; Marshall M; Lovegrove R; Longman RJ; Lloyd J; Lim J; Lee K; Korwar V; Hughes D; Hill G; Harris R; Hamdan M; Brown HG; Gooberman-Hill R; Glasbey J; Fryer C; Ellis L; Elliott D; Dumville JC; Draycott T; Donovan JL; Cotton D; Coast J; Clout M; Calvert MJ; Byrne BE; Brown OD; Blencowe NS; Bera KD; Bennett J; Bamford R; Bakhbakhi D; Atif M; Ashton K; Armstrong E; Andronis L; Ananthavarathan P; Blazeby JM
Health Technol Assess; 2019 Aug; 23(39):1-166. PubMed ID: 31392958
[TBL] [Abstract][Full Text] [Related]
20.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
